Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The DAHANCA 6 randomized trial: Effect of 6 vs 5 weekly fractions of radiotherapy in patients with glottic squamous cell carcinoma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Diffusion MRI outlined viable tumour volume beats GTV in intra-treatment stratification of outcome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Diabetes increases the risk of serious adverse events after re-irradiation of the spine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Influence of volumetric modulated arc therapy and FET-PET scanning on treatment outcomes for glioblastoma patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. NTCP model validation method for DAHANCA patient selection of protons versus photons in head and neck cancer radiotherapy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. A prospective, multicenter DAHANCA study of hyperfractionated, accelerated radiotherapy for head and neck squamous cell carcinoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

PURPOSE: The DAHANCA 6 trial evaluated tumor response and morbidity after moderate accelerated radiotherapy compared to conventional fractionated radiotherapy in patients treated for glottic squamous cell carcinoma (SCC). Further, the failure pattern and incidence of new primary tumors were explored.

PATIENTS AND METHODS: Six hundred and ninety-four patients with non-metastatic glottic SCC were randomized between six or five weekly fractions (fx/w) of radiotherapy to the same total dose. The median treatment time was 38 and 46days, respectively. The primary endpoint was loco-regional failure.

RESULTS: Median follow-up time was 14.5years. Of the 177 failures, 167 involved T-site. The cumulative incidence of loco-regional failure (LRF) was 21.6% in the 6fx/w group and 29.3% in the 5fx/w group and the corresponding hazard rate (HR) of LRF was 0.72 (CI: 0.53-0.97, p=0.04). The effect of acceleration on LRF was especially evident in well differentiated tumors (HR=0.42 (CI: 0.23-0.75) and in T1-2 tumors (HR=0.60 (CI: 0.41-0.89)). The HR of laryngectomy was 0.72 (CI: 0.50-1.04) in the 6fx/w group compared to the 5fx/w group. The hazards of disease-specific death, event-free survival, and overall survival were comparable between the two groups. Significantly more patients experienced severe acute mucositis in the 6fx/w group but the incidence of late morbidity was comparable between the groups. New primary tumors occurred in 22.5% of the patients.

CONCLUSION: Moderate accelerated radiotherapy significantly improved loco-regional control in patients with glottic SCC.

OriginalsprogEngelsk
TidsskriftRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Vol/bind117
Udgave nummer1
Sider (fra-til)91-8
Antal sider8
ISSN0167-8140
DOI
StatusUdgivet - okt. 2015

ID: 45900510